Please note: In response to the COVID-19 pandemic our staff is working remotely, and all services remain fully operational. Orders for print and eBooks are currently being processed and fulfilled. Thank you for your patience as we strive to serve you during this challenging time. Please email us if you have any questions.


Click to Enlarge

Add To Cart

Hepatitis C Virus: The Story of a Scientific and Therapeutic Revolution

Subject Area(s):  Infectious DiseasesHuman Biology and DiseaseDiseasesViruses

Edited by Arash Grakoui, Emory University; Jean-Michel Pawlotsky, Hopital Henri Mondor / Universite Paris Est; Glenn Randall, University of Chicago

Due July 2020 • 300 pages (approx.), illustrated, index
Hardcover • $135 94.50
ISBN  978-1-621823-19-3
You save: 30%
You will receive free shipping on this item at checkout.
Free shipping offer applies to direct website purchases by individual U.S. and Canada customers only.

  •     Description    
  •     Contents    


Hepatitis C is a liver disease caused by infection with the hepatitis C virus (HCV), a bloodborne pathogen. In some people, an immune response will clear the infection; however, in most, the infection becomes chronic and treatment with antiviral medication is necessary to prevent serious liver damage and cancer. The eradication of HCV will require improved access to diagnosis and treatment, an enhanced understanding of virus–host interactions, and the development of an effective vaccine.

Written and edited by experts in the field, this collection from Cold Spring Harbor Perspectives in Medicine examines all aspects of the biology of HCV, the pathological consequences of infection, the current standard of hepatitis C treatment, and ongoing efforts to control the disease. Contributors discuss the structural and biochemical properties of HCV, the molecular details of its life cycle, and how it promotes liver disease by perturbing host cell signaling pathways. They likewise examine the innate and adaptive immune responses elicited by HCV and why those responses often fail to clear the infection. Direct-acting antiviral regimens to treat infected patients, the impacts of those treatments on hepatitis C epidemiology, and obstacles to HCV elimination (e.g., vaccine development) are also covered.

This volume includes additional perspectives on the discovery of HCV, historical milestones in HCV research, and animal and cell culture models of HCV infection. It is an essential reference for virologists, immunologists, and all clinical and laboratory investigators interested in eliminating HCV as a public health threat.


1. HCV: 30 years since its identification
Michael Houghton
2. HCV genetic heterogeneity
Jens Bukh
3. HCV Structure
Joseph Marcotrigiano and Maria Theresa Catanese
4. Cell Culture Systems of HCV Using JFH-1 and Other Strains
Takaji Wakita
5. Animal Models of Hepatitis C Virus Infection
Alexander Ploss and Amit Kapoor
6. Hepatitis C Virus Entry: Protein Interactions and Fusion Determinants Governing Productive Hepatocyte Invasion
Gisa Gerold, Rebecca Moeller, and Thomas Pietschmann
7. HCV Replication
Ralf Bartenschlager, Keisuke Tabata, and Christopher Neufeldt
8. HCV Assembly and Egress Via Modifications in Host Lipid Metabolic Systems
Kunitada Shimotohno
9. HCV-host interactions in cellular pathogenesis
Qisheng Li and Jake Liang
10. Cellular innate immune control of HCV infection
Michael Gale and Ram Savan
11. Control of HCV infection by NK cells and macrophages
Hugo Rosen & Lucy Golden-Mason
12. T cell control of HCV infection
Chris Walker
13. Role of antibodies in HCV infection
Mansun Law
14. Interferon-free HCV therapy
Jean-Michel Pawlotsky
15. Heptatis C Virus Epidemiology and the Impact of Interferon-free HCV Therapy
Jeffrey V. Lazarus, Elena Roel, and Ahmed M. Elsharkawy
16. Natural History of Hepatic and Extrahepatic HCV Diseases and Impact of Interferon-Free HCV Therapy
Francesco Negro
17. Elimination of hepatitis C as a public health threat
Sophia Schroeder, Alisa Pedrana, Joseph Doyle, Campbell Aitken, and Margaret Hellard
18. Pros and cons of an HCV vaccine
Andrea Cox
19. Future Perspectives
Jean-Michel Pawlotsky, Arash Grakoui, and Glenn Randall